Biology Reference
In-Depth Information
[118] Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for
chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus
prednisone versus prednisone alone. Blood 2002;100:48-51.
[119] Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, et al. Randomized
clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and
prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow
Transplant 2001;7:265-73.
[120] Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R, et al. Efficacy
of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol
Blood Marrow Transplant 2005;11:307-13.
[121] Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, et al. Different efficacy of mycophe-
nolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem
cell transplant. Eur J Haematol 2004;73:56-61.
[122] Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Myco-
phenolate mofetil for the treatment of acute and chronic GVHD is effective and well
tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC
transplant patients. Bone Marrow Transplant 2002;30:287-95.
[123] Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, et al.
Rapamycin (Sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood
Marrow Transplant 2005;11:47-55.
[124] Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, et al. Sirolimus in combi-
nation with Tacrolimus and corticosteroids for the treatment of resistant chronic graft-
versus-host disease. Br J Haematol 2005;130:409-17.
[125] Jurado M, Vallejo C, Perez-Simon JA, Brunet S, Ferra C, Balsalobre P, et al. Sirolimus as
part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Biol Blood Marrow Transplant 2007;13:701-6.
[126] Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus
Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic
graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1-7.
[127] Whittle R, Taylor PC. Circulating B-cell activating factor level predicts clinical re-
sponse of chronic graft-versus-host disease to extracorporeal photopheresis. Blood
2011;118:6446-9.
[128] Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, et al. Extracorpo-
real photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood
2006;107:3074-80.
[129] Kanold J, Messina C, Halle P, Locatelli F, Lanino E, Cesaro S, et al. Update on extra-
corporeal photochemotherapy for graft-versus-host disease treatment. Bone Marrow
Transplant 2005;35(Suppl. 1):S69-71.
[130] Gutierrez-Aguirre CH, Cantu'-Rodriguez OG, Borjas-Almaguer OD, Gonzalez-Llano O,
Jaime-Perez JC, Solano-Genesta M, et al. Effectiveness of subcutaneous low-dose alem-
tuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-
host disease. Haematologica 2011;97:717-22.
[131] Majhail NS, Schiffer CA, Weisdorf DJ. Improvement of pulmonary function with
imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell
transplantation. Biol Blood Marrow Transplant 2006;12:789-91.
[132] Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, et al. Imatinib
for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009;114:
709-18.
[133] Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, et al. Imatinib mesyl-
ate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood
2009;114:719-22.
[134] Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo expansion of human
Tregs specific for alloantigens presented directly or indirectly. Blood 2011;118:
5671-80.
[135] Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, et al. Massive
ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of
in vivo functional activity. Sci Transl Med 2011;3; 83ra41.
[136] Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS, et al. Recov-
ery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood
2011;117:2275-83.
[137] Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, et al. A phase
1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28
costimulation. Blood 2006;107:1325-31.
[138] Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR, et al. Therapy of relapsed
leukemia after allogeneic hematopoietic cell transplantation with T cells specific for
minor histocompatibility antigens. Blood 2010;115:3869-78.
324
Search WWH ::
Custom Search